The first generic versions of GlaxoSmithKline’s cardiovascular agent Coreg – all 14 of them – have been approved by US regulators. The first generic versions of GlaxoSmithKline’s cardiovascular agent ...

Following a more than decade-long legal back-and-forth over the generic drug carveout practice known as “skinny” labeling, GSK and Teva have put their dispute to bed, new court documents show. In a ...

A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. A ...

Please provide your email address to receive an email when new articles are posted on . Two preparations of carvedilol given to patients with heart failure were found nearly bioequivalent. Researchers ...

The US Food and Drug Administration has approved a label update for GlaxoSmithKline’s Coreg (carvedilol), meaning that the beta-blocker is now available to reduce the risk of suffering a heart attack.

Prove it, GlaxoSmithKline. So says a judge in the Coreg patent case that last year ended in a $235 million judgment against generics maker Teva. In the patent "carve-out" case, GSK didn't bring enough ...

November 17, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise on the use of carvedilol tablets in diabetic patients; the risk for potentially fatal ...

Carvedilol is a generic drug that’s prescribed for heart failure, high blood pressure, or certain heart problems following a heart attack. It’s available as the brand-name drug Coreg. The cost of ...

Carvedilol (as phosphate) 10mg, 20mg, 40mg, 80mg; ext-rel caps. Coreg CR are supplied as hard gelatin capsules in bottles of 30 in the following strengths: 10 mg – white and green capsule shell ...